JPS6127909A - External drug for skin - Google Patents
External drug for skinInfo
- Publication number
- JPS6127909A JPS6127909A JP14836884A JP14836884A JPS6127909A JP S6127909 A JPS6127909 A JP S6127909A JP 14836884 A JP14836884 A JP 14836884A JP 14836884 A JP14836884 A JP 14836884A JP S6127909 A JPS6127909 A JP S6127909A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- methyl
- dimethoxy
- drug
- henzenediol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title abstract description 7
- 229940079593 drug Drugs 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 6
- 230000001235 sensitizing effect Effects 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract description 2
- 229960004337 hydroquinone Drugs 0.000 abstract 2
- DSBZYDDWLLIJJS-UHFFFAOYSA-N ubiquinol-0 Chemical class COC1=C(O)C=C(C)C(O)=C1OC DSBZYDDWLLIJJS-UHFFFAOYSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000012071 phase Substances 0.000 description 18
- 239000003921 oil Substances 0.000 description 11
- -1 thiol compounds Chemical class 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 230000002087 whitening effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000005342 ion exchange Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000003518 caustics Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 235000011118 potassium hydroxide Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N aniline-p-carboxylic acid Natural products NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- ULBTUVJTXULMLP-UHFFFAOYSA-N butyl octadecanoate Chemical group CCCCCCCCCCCCCCCCCC(=O)OCCCC ULBTUVJTXULMLP-UHFFFAOYSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- ZLVYMPOQNJTFSG-QMMMGPOBSA-N monoiodotyrosine Chemical compound OC(=O)[C@@H](NI)CC1=CC=C(O)C=C1 ZLVYMPOQNJTFSG-QMMMGPOBSA-N 0.000 description 1
- 239000008164 mustard oil Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は皮膚外用剤、さらに詳しくは美白効果が著しく
改良された安全性の高い皮膚外用剤に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a skin external preparation, and more particularly to a highly safe skin external preparation with significantly improved whitening effects.
皮膚のしみなどの発生機序につい−Cは不明な点もある
が、一般には、ホルモンの異常や紫外線の刺激が原因と
なってメラニン色素が形成され、これが皮膚内に異常沈
着するものと考えられている。Although there are some unknown points regarding the mechanism of occurrence of skin spots, it is generally thought that melanin pigment is formed due to hormonal abnormalities or stimulation from ultraviolet rays, and this is abnormally deposited in the skin. It is being
このようなじみやあざの治療法にはメラニンの生成を抑
制する物質、例えばビタミンC、グルタチオン、システ
ィンなどを大量に投与する方法、注射する方法あるいは
、軟膏、クリーム、ローションなどの形態にして局所に
塗布するなどの方法がとられている。また欧米ではハイ
ドl:Jキノン製剤が医薬品として用いられている。し
かしながら、ビタミンC類は安定性の面で問題があり、
とくに水分を含む系では不安定で変色、変5!、の原因
となるし、グルタチオン、システィンなどのチオール系
化合物は異臭が強い上、酸化されやすいので化粧料への
配合は避けられている。Treatments for such bruises include the administration of large doses of substances that inhibit melanin production, such as vitamin C, glutathione, and cysteine, injections, or topical administration in the form of ointments, creams, and lotions. Methods such as coating are used. Furthermore, in Europe and America, Hyde l:J quinone preparations are used as pharmaceuticals. However, vitamin C has problems in terms of stability.
Particularly in systems containing water, it is unstable and may cause discoloration or discoloration5! , and thiol compounds such as glutathione and cysteine have a strong odor and are easily oxidized, so their inclusion in cosmetics is avoided.
さらにこれらの化合物はハーイドロキノンを餘いてはそ
の効果の発現がきわめて伝慢であるため、美白効果が十
分でない。一方、ハーイトロキノンは効果は一応認めら
れているが、強い感作性を有するため、一般には使用が
制限されている。Furthermore, these compounds do not have a sufficient whitening effect because their effects are extremely slow to appear when hydroquinone is added. On the other hand, although the effect of hytroquinone has been recognized to some extent, its use is generally restricted because it has strong sensitizing properties.
このような事情にかんがみ、本発明者らは鋭意研究を正
ねた結果、前記一般式(I)又は(II>の化合物がき
わめて皮膚安全性にすぐれζおり、また安定性もよく、
さらに美白効果もへイドロキノンとほぼ同程度に発揮す
ることを見いだし、本発明を完成するに至った。In view of these circumstances, the present inventors have carried out extensive research and have found that the compound of the general formula (I) or (II>) has excellent skin safety, and also has good stability.
Furthermore, it was discovered that the whitening effect is almost the same as that of hehydroquinone, leading to the completion of the present invention.
すなわち、本発明は、下記一般式(T)及び(n)で表
される化合物よりなる群から選ばれた一種又は二種以上
を含有することを特徴とする皮膚外用剤である。That is, the present invention is an external skin preparation characterized by containing one or more compounds selected from the group consisting of compounds represented by the following general formulas (T) and (n).
1式(T)、(n)中、n=1〜10](以′下余白) 以下に本発明の構成について述べる。1 formula (T), (n), n = 1 to 10] (below margin) The configuration of the present invention will be described below.
本発明に用いられる一般式(I)の化合物としては例え
ば2.3〜ジメトキシ−5−メチル−6−プレニル−1
,4ヘンゼネジオール(n=1)い23−ヅメ1−キシ
−5−メチル−6−ジプレニルー1,4−ペンゼネジオ
ール(n=2) 、2.3−ジメトキシ−5−メチル−
6−へブタプレニル−L4−−ベンゼネジオール(n=
7) 、2.3=ジメトキシ−5−メチル−6−ゾカプ
レニルー14−ヘンゼネジオール(n−10)などを挙
げることができ、一般式(II)の化合物としては、例
えば、2,3−ジメトキシ−5−メチル−〇−(3’、
7’、11’+15’、19“+23’+27’+−ヘ
プタノチル−オフフコシル)−1,4−ヘンゼネジオー
ル(n=7)、2.3−ジメトキシ−5−メチル−6−
(3’、7’、11’、15’、19’、23’、27
’、31’、−オククメチルードトリアコンチル)1.
4−ペンゼネジオール(n=8) 、2.3−ジメトキ
シ−5−メチル−6−(3°、7’、11’、15’、
19’、23′、27′、31’、35’、39−デカ
メチルータ1ラコンチル)−14−ヘンゼネジオール(
n=”io)などを挙げることができる。Examples of the compound of general formula (I) used in the present invention include 2.3-dimethoxy-5-methyl-6-prenyl-1
, 4-penzenediol (n=1), 23-dimethoxy-5-methyl-6-diprenyl-1,4-penzenediol (n=2), 2,3-dimethoxy-5-methyl-
6-hebutaprenyl-L4--benzenediol (n=
7), 2.3=dimethoxy-5-methyl-6-zocaprenyl-14-henzenediol (n-10), etc., and examples of the compound of general formula (II) include 2,3-dimethoxy -5-methyl-〇-(3',
7', 11'+15', 19"+23'+27'+-heptanotyl-offucosyl)-1,4-henzenediol (n=7), 2,3-dimethoxy-5-methyl-6-
(3', 7', 11', 15', 19', 23', 27
', 31', -occumethyldotriacontyl)1.
4-penzenediol (n=8), 2,3-dimethoxy-5-methyl-6-(3°, 7', 11', 15',
19', 23', 27', 31', 35', 39-decamethylta-1 lacontyl)-14-henzenediol (
For example, n=”io).
本発明においては、上記のうぢから選ばれた任意の一種
又は二種以上が用いられる。In the present invention, any one or more selected from the above may be used.
配合量は一般的に0.0001〜10重量%であり、好
ましくは0.01〜5重量%である。The blending amount is generally 0.0001 to 10% by weight, preferably 0.01 to 5% by weight.
つぎに、本発明の美白ノl果について試験した結果につ
いて説明する。美白す】果の指標としては一般に用いら
れているメラニン生成の酸化酵素チロシナーゼを阻害す
る割合で表ず方法を用いた。Next, the results of testing the whitening fruit of the present invention will be explained. [Skin Whitening] As an indicator of the fruit, a method was used in which the rate of inhibition of tyrosinase, an oxidative enzyme for melanin production, which is commonly used, was used.
チロシナ ゼ阻害
チロシナーゼ阻害率はドーパを基質として次に示す手順
でおこなった。Tyrosinase Inhibition Tyrosinase inhibition rate was determined using DOPA as a substrate using the following procedure.
試料溶液
2.3−ジットキシ−5−メチル−6−ゾカブレニルー
1,4−ヘンゼネジオール12tngをアセトン10m
1に熔解する。Sample solution 2. 12 tng of 3-ditoxy-5-methyl-6-zocabreny-1,4-henzenediol was added to 10 ml of acetone.
Melt to 1.
基質溶液
ドーパ5 m=をリンM緩衝’1g液(I/ 1¥rニ
ル、pl+6.8 ) IQmlに溶解する。Dissolve 5 m of substrate solution Dopa in 1 g of phosphorus M buffer (I/1\r, pl+6.8) IQml.
酵素ン容ン1(ζ
ヂロシナーゼ(2000単位、/ mg、シグマ社)
10mgをリン酸ン妥fIiンイk(]/15モル、p
l!6.8 ) にン容解して10m1とする。Enzyme 1 (ζ Dirosinase (2000 units, / mg, Sigma)
10 mg of phosphoric acid (]/15 mol, p
l! 6.8) Dissolve to make 10ml.
測定
試料0.5mlに酵素溶液0.05n+lおよびリン酸
緩衝溶液0.45m1を加え、25°Cで5分間インキ
ユヘー トする。これにあら、〕1しめ25°Cてイン
牛ユベートした酵素溶液0.5mlを加えて1.5分間
反応させ、475nmの吸光度を測定した。Add 0.05 n+l of enzyme solution and 0.45 ml of phosphate buffer solution to 0.5 ml of the measurement sample, and incubate at 25°C for 5 minutes. To this, 0.5 ml of an enzyme solution incubated at 25° C. was added, reacted for 1.5 minutes, and the absorbance at 475 nm was measured.
阻害率は次式によって算出し、2,3−ジメトキシ−5
−メチル−6−ゾカプレニルー1.4−ヘンゼネジオー
ルの阻害率は55.1%(C度0.06%との結果を冑
た。The inhibition rate was calculated by the following formula, and 2,3-dimethoxy-5
The inhibition rate of -methyl-6-zocaprenyl-1,4-henzenediol was 55.1% (C degree 0.06%).
T−T’
阻害率−(i −−−−−−一−−> x 1o o
<%)c−c ’
T :阻害剤を添加した場合の吸光度
T′:阻害剤を添゛加し、基質をくわえない場合の吸光
度
C:阻害剤を添加しない場合の吸光度
C′:阻害剤も基質も加えない場合の吸光度ごれから明
らかな如く、本発明で用いられる2、3−ジノ1−キシ
−5−メチル−6−ゾカプレニルー1..4−ヘンゼネ
ジオールは良好なチロキシナーゼ活性の阻害作用を有す
ることがわかる。T-T' Inhibition rate - (i --------1--> x 1o o
<%) c-c' T: Absorbance when inhibitor is added T': Absorbance when inhibitor is added and no substrate is added C: Absorbance when no inhibitor is added C': Inhibitor As is clear from the absorbance scattering when neither substrate nor substrate is added, 2,3-dino-1-xy-5-methyl-6-zocaprenyl 1. .. It can be seen that 4-henzenediol has a good inhibitory effect on thyroxinase activity.
本発明の皮膚外用剤は、クリーム、化粧水、乳液、パン
ク、石鹸、軟膏などの形態とすることができる。The external skin preparation of the present invention can be in the form of cream, lotion, emulsion, puncture, soap, ointment, and the like.
本発明の皮J7:嶽ト用剤は、上記の必須成分に加えて
、必要に応して、本発明の効果を損なわない量的、質的
範囲内で、保湿剤、界面活性剤、顔料、香料、防腐剤、
酸化防止剤、キレ−1−剤、皮IW栄養剤、毛髪栄養剤
、酵素等が配合される。皮層゛栄養剤、毛髪栄従剤、酵
素としては、例えばヨードチロシンおよびその誘導体、
メチオニンおよびその誘導体、リジン、セリン、グリコ
コ ルおよびそれらの誘導体等のアミノ酸、パントテン
酸、ビオチン、ビタミンI32、ヒクミンBL+、二」
ヂン酸、ビタミンD、ビタミンF等のビタミン類、女性
ホルモン、脳TTi体ボルモン、酵素ホスホリラーゼ等
の酵素およびホルモン類、その他イノシトール、オロチ
ン酸、チオクト酸、コンドロイチン硫酸等が挙げられる
。Skin J7 of the present invention: In addition to the above-mentioned essential ingredients, if necessary, within a quantitative and qualitative range that does not impair the effects of the present invention, the skin preparation may contain a moisturizing agent, a surfactant, and a pigment. , fragrances, preservatives,
Antioxidants, cleaning agents, skin IW nutrients, hair nutrients, enzymes, etc. are blended. Examples of skin layer nutrients, hair care agents, and enzymes include iodotyrosine and its derivatives,
Amino acids such as methionine and its derivatives, lysine, serine, glycocol and their derivatives, pantothenic acid, biotin, vitamin I32, Hikumin BL+, 2.
Examples include vitamins such as dinic acid, vitamin D, and vitamin F, female hormones, brain TTi body bolmon, enzymes and hormones such as the enzyme phosphorylase, and other substances such as inositol, orotic acid, thioctic acid, and chondroitin sulfate.
またシミ、ソバカス等の予防治療には紫外線吸収剤を加
えると−f効果的である。Furthermore, it is effective to add an ultraviolet absorber to prevent stains, freckles, etc.
紫外線吸収剤の例としては、パラアミノ安息香酸エチル
エステル、パラジノチルアミノ安息香酸エチルへ、ギシ
ルエステル、シノキザ−1〜、パラ7′トキソ+I 皮
U(iエチルヘギシルエステル、2.2’−4,4’−
−テトラハイドロオキシヘンシフエノン、2−しドロキ
シ−・1−メI−キシヘンシフエノン又は・とのスルフ
ォン酸塩(八5L−245) 、・シロカニン酸等を挙
げることができる。Examples of ultraviolet absorbers include para-aminobenzoic acid ethyl ester, para-dinotylaminobenzoic acid ethyl ester, cynoxa-1~, para-7' toxo+I skin U (i ethylhegysyl ester, 2.2'-4 ,4'-
Examples include -tetrahydroxyhensiphenone, sulfonic acid salts of 2-droxy-.1-me-I-xyhensiphenone or (85L-245), and silicanic acid.
本発明の皮爪外用剤は無刺激で感作性が殆んどなく、し
たがって長期連用使用、高濃度使用も可能であり、皮膚
美白効果を十分に発揮させることができる。The skin and nail external preparation of the present invention is non-irritating and has almost no sensitization, so it can be used continuously for a long period of time and in high concentrations, and can fully exhibit its skin whitening effect.
つき゛に実施例を挙げて本発明をさらに詳しく説明する
。本発明はこれにより限定されるものではない。配合■
は重量%である。The present invention will be explained in more detail by referring to examples. The present invention is not limited thereby. Combination■
is weight %.
[実M+i例1 ]ハニシングクリームステアリン酸
5.0ステアリルアルコ
ール 4.0ステアリン酸ブチルア
ルコールエステル 8.0グリセリンモノステアリン
酸エステル 2.0プ1コピレンゲリコール
10.02.3−ジットキン−5−ノナル
ー6−デカプレニル−1,4−ヘンゼネジオール
4.0苛性カリ
0.2防腐剤・酸化防止剤
適量香料 適量
イオン交換水 残余(製法
)
イオン交換水にプロピレングリコール、苛性カリを加え
溶解し加熱して70°Cに保つ(水相)。[Actual M+i example 1] Honey cream stearic acid
5.0 Stearyl alcohol 4.0 Stearic acid butyl alcohol ester 8.0 Glycerin monostearic acid ester 2.0 Copylene gelicol
10.02.3-Jitquin-5-nonal-6-decaprenyl-1,4-henzenediol
4.0 caustic potash
0.2 Preservatives/antioxidants
Appropriate amount of fragrance Appropriate amount of ion-exchanged water Remainder (manufacturing method) Add propylene glycol and caustic potassium to ion-exchanged water, dissolve, heat, and keep at 70°C (water phase).
他の成分を混合し加熱して70°Cに保つ(油相)。Mix other ingredients and heat and keep at 70°C (oil phase).
水相に油相を除々に加え全部加え終ってからしばらくそ
の温度に保ち反応をおこなわせる。その後ボ、モミキサ
−で均一に乳化し、よくかきまぜながら30℃まで冷却
する。Gradually add the oil phase to the aqueous phase, and once all has been added, keep at that temperature for a while to allow the reaction to occur. Then, use a rice mixer to uniformly emulsify the mixture, and cool to 30°C while stirring well.
(以下余白)
U実施例2コ中性クリーム
ステアリルアルコール 7.0ステ
アリン酸 2.0スクワ
ラン 5,0水添ラノリ
ン 2.02−オクチルド
デシルアルコール 6.0ポリオキシエチレ
ン(25モル)セチルアルコールエーテル
3.Qグリセリンモノステアリン酸コニステ
ル 2.0プロピレングリコール
5.02.3−ジメトキシ−5−メチル−6−(3
’、7’。(Left below) U Example 2 Neutral cream Stearyl alcohol 7.0 Stearic acid 2.0 Squalane 5,0 Hydrogenated lanolin 2.0 2-Octyldodecyl alcohol 6.0 Polyoxyethylene (25 mol) Cetyl alcohol ether
3. Q Glycerin Monostearate Conistere 2.0 Propylene Glycol
5.02.3-dimethoxy-5-methyl-6-(3
',7'.
11’、15’、19’、23’、27°−へブタメチ
ル−6オククコシル)−1,4−ヘンゼネジオール 1
.52.3−ジメトキシ−5−メチル−6−へブタプレ
ニル−L4−ペンゼネジオール 1.5香料
適量防腐剤・酸
化防止剤 適量イオン交換水
残余(製法)
イオン交換水にプロピレングリコールを加え加ζ;4ル
で70℃に保つ(水相)。他の成分を混合して加熱融解
して70℃に保つ(油相)。水相に油相を加え、予備乳
化をJ、ごない、ホモミキサーで均一に乳化し、乳化後
冷却しながらかきまぜる。11', 15', 19', 23', 27°-hebutamethyl-6occucosyl)-1,4-henzenediol 1
.. 52.3-dimethoxy-5-methyl-6-hebutaprenyl-L4-penzenediol 1.5 Fragrance
Appropriate amount of preservatives and antioxidants Appropriate amount of ion exchange water
Residue (manufacturing method) Add propylene glycol to ion-exchanged water and keep at 70°C for 4 hours (water phase). Mix other ingredients, heat and melt and keep at 70°C (oil phase). Add the oil phase to the aqueous phase, homogeneously emulsify the pre-emulsification using a homomixer, and after emulsification stir while cooling.
(以下余白)
[実施例3ココールドクリーム
固形パラフィン 4.0ミツ
ロウ 8.0ワセリ
ン 12,0流動パラ
フイン 35.0グリセリン
モノステアリン酸エステル 2.0ポリオキシエチ
レン(20モル)
ソルビクンモノラウリン酸エステル2.0石けん粉末
0.1ボウ砂
0.22.3−ジメトキシ−5
−メチル−6−(3’、7’。(Left below) [Example 3 Coco Cold Cream Solid paraffin 4.0 Beeswax 8.0 Vaseline 12.0 Liquid paraffin 35.0 Glycerin monostearate 2.0 Polyoxyethylene (20 mol) Sorbicun monolaurate 2 .0 soap powder
0.1 bow sand
0.22.3-dimethoxy-5
-Methyl-6-(3', 7'.
11’+15’、19’、23’+27’+31’、3
5’−ノナメチル−・キザトリアコンチル) −L4
−ヘンゼネジオール 10.0
イオン交扱水 残余香料
適量防腐剤・酸
化防止剤 適量(製法)
イオン交換水に石けん粉末、ホウ砂を加え加熱溶解して
70″Cに保つ(水相)。他の成分を混合し加熱熔解し
て70°Cに保つ(油相)。水相に油相をかきまぜなが
ら徐々に加え反応をおこなう。反応終了後ホモミキサー
で均一に乳化し、乳化後よくかきまぜなから30°Cま
で冷却する。11'+15', 19', 23'+27'+31', 3
5'-nonamethyl-quizatriacontyl) -L4
-Henzenediol 10.0
Ion exchange water Residual fragrance
Appropriate amount Preservative/Antioxidant Appropriate amount (manufacturing method) Add soap powder and borax to ion-exchanged water, heat and dissolve, and maintain at 70"C (water phase). Mix other ingredients, heat and melt, and maintain at 70°C. Keep (oil phase). Gradually add the oil phase to the aqueous phase while stirring and react. After the reaction is complete, emulsify uniformly with a homomixer, and after emulsification, stir well and cool to 30°C.
[実施例4]乳 液
ステアリン酸 2.5セ
チルアルコール 2.0ワセリ
ン 5.0流動パラフ
イン 10,0ボリオギシエ
チレン(I0モル)
モノオレイン酸エステル 2.0ポリ
エチレングリコール1500 3.01−
リエタノールアミン 1,02.
3−ジメトキシ−5−メチル−6−ゾカプレニルー1,
4−ヘンゼネジオール 1.0イオン交換
水 残余香料
適量防腐剤・酸化防止剤
適量(製法)
イオン交換水にポリエチレングリコール、!・リエタノ
ールアミンを加え加熱溶解して70℃に保つ(水相)。[Example 4] Emulsion Stearic acid 2.5 Cetyl alcohol 2.0 Vaseline 5.0 Liquid paraffin 10.0 Polyethylene (I0 mol) Monooleic acid ester 2.0 Polyethylene glycol 1500 3.01-
Reethanolamine 1,02.
3-dimethoxy-5-methyl-6-zocaprenyl 1,
4-henzenediol 1.0 ion exchange water residual fragrance
Appropriate amount of preservatives and antioxidants
Appropriate amount (manufacturing method) Polyethylene glycol in ion exchange water!・Add reethanolamine, dissolve by heating, and keep at 70°C (aqueous phase).
他の成分を混合し、加熱溶解し7て70゛Cに保つ(油
相)。水相に油相を加え予備乳化をおこないホモミキサ
ーで均一に乳化し、乳化後かきまぜながら30℃まで冷
却する。Mix other ingredients, heat and dissolve and maintain at 70°C (oil phase). The oil phase is pre-emulsified by adding the oil phase to the water phase, and the mixture is uniformly emulsified using a homomixer. After emulsification, the mixture is cooled to 30°C while stirring.
(以下余白)
[実施例5]化粧水
(アルコール相)
95%エタノール 21.0
ポリオキシエチレン(60モル)
硬化しマシ油エーテル 1.4防腐
剤・酸化防止剤 適量香料
■2.3−ジフトキン
−5−メチル−6−(3”、7′。(Left below) [Example 5] Lotion (alcohol phase) 95% ethanol 21.0
Polyoxyethylene (60 moles) Hardened mustard oil ether 1.4 Preservatives/antioxidants Appropriate amount Fragrance
■2.3-diphthoquine-5-methyl-6-(3", 7'.
11’、15’、19’、23’、27’、31’、3
5’、39’−デカノチルーテ1ラコンチル) −1,
4−ヘンゼネジオール 0.1
(水相)
グリセリン 5.02−ヒド
ロキシ−4−メトキシヘンシフエノン−5−スルフオン
酸ナトリウム 0.3ヘキサツクリン酸
ナトリウム 3!I[iイオン交換水
残余(g法)
水相、アルコール相を調整後可溶化する。11', 15', 19', 23', 27', 31', 3
5', 39'-decanothylute 1 lacontyl) -1,
4-henzenediol 0.1
(Aqueous phase) Glycerin 5.0 Sodium 2-hydroxy-4-methoxyhensiphenone-5-sulfonate 0.3 Sodium hexaclate 3! I [i ion exchange water
Residue (method g) After adjusting the aqueous phase and alcohol phase, solubilize.
[実施例6]ゼリー
95%コニタノール 10
.Oジプロピレングリコール 15.
0ポリオキシエチレン(I5モル)
オレイルアルコールエーテル 2.0カル
ボキシビニルポリマー 1.0(商品
名:カーボ犬−ル941)
苛性カリ 0.15
L−アルギニン 0.12.
3−ジノI・キシ−5−rメチル−6−ジプレニルー1
,4−ペンゼネジオール 0.01ウロ
カニン酸 0.1香料
適量防腐剤
適量イオン交換水
残余(製法)
イオン交換水にカーボボール941を均一に溶解し、一
方、95%エタノールにジプロピレングリコール、ポリ
オキシエチレン(I5モル)オレイルアルコールエーテ
ル、2.3−ジメトキシ−5−メヂルー6テカブレニ月
ハ1.+i−ヘンゼネジオール及びその他の成分を熔解
し、水相に添加する。ついで苛性カリ、L−アルギニン
で中和させ増粘する。[Example 6] Jelly 95% conitanol 10
.. O dipropylene glycol 15.
0 Polyoxyethylene (I5 mol) Oleyl alcohol ether 2.0 Carboxy vinyl polymer 1.0 (Product name: Carbodogol 941) Caustic potash 0.15
L-arginine 0.12.
3-dino I xy-5-rmethyl-6-diprenyl-1
,4-penzenediol 0.01 urocanic acid 0.1 fragrance
Appropriate amount of preservative
Appropriate amount of ion exchange water
Residue (manufacturing method) Carboball 941 was uniformly dissolved in ion-exchanged water, while dipropylene glycol, polyoxyethylene (I 5 mol) oleyl alcohol ether, 2,3-dimethoxy-5-methylene 6 tecabreni were dissolved in 95% ethanol. C1. +i-henzenediol and other ingredients are melted and added to the aqueous phase. Then, it is neutralized and thickened with caustic potassium and L-arginine.
[実施例7]吸水軟合
ワセリン 40.0
ステアリルアルニ7−ル 13.0
モクロウ 15.0ポ
リオキシエチレン(I0モル)
モノオレイン酸エステル 0.25グ
リセリンモノステアリン酸エステル 0,252.
3−ジメトキシ−5−ノナルー6−プレニル−114−
ヘンゼネジオ−ル 10.0イオン交換
水 残余(製法)
イオン交換水を70℃に保つ(水相)。他の成う〕を7
0°Cにて混合i容解する(油相)。水相に油相を加え
、ボモミギザーで均一・に乳化後冷却する。[Example 7] Water-absorbing soft vaseline 40.0
Stearyl alniole 13.0
Mokuro 15.0 Polyoxyethylene (I0 mol) Monooleic acid ester 0.25 Glycerin monostearic acid ester 0,252.
3-dimethoxy-5-nonal-6-prenyl-114-
Henzenediol 10.0 Ion-exchanged water Residual (manufacturing method) Keep ion-exchanged water at 70°C (aqueous phase). 7
Mix and dissolve at 0°C (oil phase). Add the oil phase to the water phase, homogeneously emulsify with a bomomi grinder, and then cool.
実施例1〜7の皮m゛外用剤は全て日焼けした皮膚を淡
白化する等美白効果に優れ、皮膚刺激性、感作性が少な
く、経時安定性にも優れていた。All of the external skin preparations of Examples 1 to 7 had excellent whitening effects such as lightening sunburned skin, had little skin irritation and sensitization, and had excellent stability over time.
Claims (1)
る群から選ばれた一種又は二種以上を含有することを特
徴とする皮膚外用剤。 ▲数式、化学式、表等があります▼( I ) [式( I )、(II)中、n=1〜10][Scope of Claims] An external skin preparation characterized by containing one or more compounds selected from the group consisting of compounds represented by the following general formulas (I) and (II). ▲There are mathematical formulas, chemical formulas, tables, etc.▼(I) [In formulas (I) and (II), n = 1 to 10]
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14836884A JPS6127909A (en) | 1984-07-17 | 1984-07-17 | External drug for skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14836884A JPS6127909A (en) | 1984-07-17 | 1984-07-17 | External drug for skin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6127909A true JPS6127909A (en) | 1986-02-07 |
Family
ID=15451199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14836884A Pending JPS6127909A (en) | 1984-07-17 | 1984-07-17 | External drug for skin |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6127909A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63188609A (en) * | 1987-01-30 | 1988-08-04 | Sansho Seiyaku Kk | External preparation preventing coloring |
| JPH0685326U (en) * | 1993-05-20 | 1994-12-06 | 勝文 伊藤 | Wig that can be divided into multiple parts |
| US5449518A (en) * | 1991-07-17 | 1995-09-12 | L'oreal | Utilization of derivatives of 2,5-dihydroxyphenyl-carboxylic acids, their homologs, and their salts in preparation of a cosmetic or dermatological composition with a depigmenting action |
| US5468472A (en) * | 1993-05-06 | 1995-11-21 | L'oreal | Topical process for lightening the skin or treating pigmental blemishes using a composition containing 4-thioresorcin derivatives |
| WO2006013665A1 (en) * | 2004-08-02 | 2006-02-09 | Kaneka Corporation | Whitening composition containing reduced coenzyme q |
| JP2006248940A (en) * | 2005-03-09 | 2006-09-21 | Eikodo Honten:Kk | Cosmetics for skin or hair |
| CN1313069C (en) * | 2001-05-10 | 2007-05-02 | 钟渊化学工业株式会社 | Composition for hair and/or scalp |
| WO2007039058A3 (en) * | 2005-09-23 | 2007-08-23 | Dsm Ip Assets Bv | Use of opioid receptor antagonists |
| JP4859914B2 (en) * | 2005-03-26 | 2012-01-25 | アウディー アーゲー | Balance shaft module |
| US10470986B2 (en) | 2013-03-08 | 2019-11-12 | Conopco, Inc. | Resorcinol compounds for dermatological use |
-
1984
- 1984-07-17 JP JP14836884A patent/JPS6127909A/en active Pending
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63188609A (en) * | 1987-01-30 | 1988-08-04 | Sansho Seiyaku Kk | External preparation preventing coloring |
| US5449518A (en) * | 1991-07-17 | 1995-09-12 | L'oreal | Utilization of derivatives of 2,5-dihydroxyphenyl-carboxylic acids, their homologs, and their salts in preparation of a cosmetic or dermatological composition with a depigmenting action |
| US5585105A (en) * | 1991-07-17 | 1996-12-17 | L'oreal | Utilization of derivatives of 2,5-dihydroxyphenylcarboxylic acids, their homologs, and their salts in preparation of a cosmetic or dermatological composition with a depigmenting action |
| US5587173A (en) * | 1991-07-17 | 1996-12-24 | L'oreal | Utilization of derivatives of 2,5 dihydroxyphenyl-carboxylic acid amides and their salts in preparation of a cosmetic or dermatological composition with a depigmenting action |
| US5637756A (en) * | 1991-07-17 | 1997-06-10 | L'oreal | Derivatives of 2,5-dihydroxyphenylcarboxylic acid |
| US5667792A (en) * | 1991-07-17 | 1997-09-16 | L'oreal | Derivatives of 2,5-dihydroxyphenylcarboxylic acids, and their utilization in cosmetic or dermatological compositions with a depigmenting action |
| US5468472A (en) * | 1993-05-06 | 1995-11-21 | L'oreal | Topical process for lightening the skin or treating pigmental blemishes using a composition containing 4-thioresorcin derivatives |
| JPH0685326U (en) * | 1993-05-20 | 1994-12-06 | 勝文 伊藤 | Wig that can be divided into multiple parts |
| AU2002309036B2 (en) * | 2001-05-10 | 2007-09-06 | Kaneka Corporation | Preparation for hair and/or scalp |
| CN1313069C (en) * | 2001-05-10 | 2007-05-02 | 钟渊化学工业株式会社 | Composition for hair and/or scalp |
| WO2006013665A1 (en) * | 2004-08-02 | 2006-02-09 | Kaneka Corporation | Whitening composition containing reduced coenzyme q |
| EP1790238A4 (en) * | 2004-08-02 | 2007-09-19 | Kaneka Corp | UBIQUINONE REDUCED CONTENT WHITENING COMPOSITION |
| JP2006248940A (en) * | 2005-03-09 | 2006-09-21 | Eikodo Honten:Kk | Cosmetics for skin or hair |
| JP4859914B2 (en) * | 2005-03-26 | 2012-01-25 | アウディー アーゲー | Balance shaft module |
| WO2007039058A3 (en) * | 2005-09-23 | 2007-08-23 | Dsm Ip Assets Bv | Use of opioid receptor antagonists |
| US10470986B2 (en) | 2013-03-08 | 2019-11-12 | Conopco, Inc. | Resorcinol compounds for dermatological use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0193519A (en) | Antipigmentation drug for external use | |
| JPS6127909A (en) | External drug for skin | |
| JPS6245527A (en) | Preventive and remedy for gray hair | |
| JPH0217115A (en) | Skin-beautifying cosmetic | |
| JP3410870B2 (en) | External preparation for skin | |
| JPH11246338A (en) | Anti-aging agent | |
| JPH11246337A (en) | Anti-aging agent | |
| JPH1129468A (en) | Protease inhibitor | |
| JPS6256411A (en) | Beautifying agent | |
| JPS63188628A (en) | Drug for skin external use | |
| JPH11246385A (en) | Antiaging agent | |
| JPS6056912A (en) | External use preparation for skin | |
| JPH1129467A (en) | Protease inhibitor | |
| JPS63183518A (en) | hair composition | |
| JPH09309841A (en) | Preparation for external use for skin | |
| JPH07149622A (en) | Beautifying and whitening preparation | |
| JPH0692833A (en) | Skin external agent | |
| JPS63246311A (en) | External agent for skin | |
| JPH11240842A (en) | Protease inhibitor | |
| JPH0354081B2 (en) | ||
| JPH11335230A (en) | Skin lotion | |
| JPH0920643A (en) | External preparation for improving chapped skin | |
| CN1232692A (en) | Antiplasmin | |
| JPH03279313A (en) | External preparation of skin | |
| JPH11209221A (en) | Preparation for external use for skin |